Abstract: Provided herein are triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.

Abstract: Disclosed herein are methods for preparing [(2S,3R)—N—[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”): and precursors thereof.

Abstract: Provided herein is a peptide epoxyketone immunoproteasome inhibitor, crystal forms, salts, and processes for making the same, and formulations thereof.

Abstract: Disclosed herein are methods for preparing [(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”): and precursors thereof.

Abstract: Provided herein is a peptide epoxyketone immunoproteasome inhibitor, crystal forms, salts, and processes for making the same, and formulations thereof.

Abstract: Provided herein are triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.

Abstract: Provided herein are triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.

Abstract: Disclosed herein are methods for preparing [(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”): and precursors thereof.

Abstract: Provided herein is a peptide epoxyketone immunoproteasome inhibitor, crystal forms, salts, and processes for making the same, and formulations thereof.

Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.

Abstract: Provided herein are triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.

Abstract: Provided herein is a peptide epoxyketone immunoproteasome inhibitor, crystal forms, salts, and processes for making the same, and formulations thereof.

Abstract: Disclosed herein are methods for preparing [(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”): and precursors thereof.

Abstract: Provided herein is a peptide epoxyketone immunoproteasome inhibitor having a structure: Formula (I) wherein X— is a counterion, crystal forms, salts, and processes for making the same, and formulations thereof.

Abstract: Disclosed herein are methods for preparing [(2S,3R)—N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”): and precursors thereof.

Abstract: Provided herein are methods of treating immune-related disorders comprising administering to a patient suffering from the disorder a therapeutically effective amount of a LMP2-selective inhibitor and a therapeutically effective amount of a LMP7-selective inhibitor. Also provided herein are compositions comprising a LMP2-selective inhibitor and a LMP7-selective inhibitor.

Abstract: A powered fastener driver includes a cylinder and a drive piston within the cylinder being acted on by a driving force resulting from a pressure differential. The powered fastener further includes a drive blade coupled to the drive piston and operable to drive a fastener, and an adjustable valve for selectively introducing air from ambient atmosphere into the cylinder, thereby changing the pressure differential acting on the drive piston. By adopting a self-contained vacuum generating means as described above, the present invention does not rely on any external vacuum source and powered fastener driver can be used and carried with conveniently.

Abstract: A device for comminuting whole trees or brush type vegetation comprising a set of more than two rotatable substantially horizontally oriented comminution drum assemblies; said set of rotatable comminution drum assemblies being constructed and arranged in an angular orientation so that the uppermost rotatable comminution drum assembly in said set of more than two substantially horizontally oriented comminution drum assemblies first engages the top portion of the whole tree or brush type vegetation and the remaining rotatable comminution drum assemblies in said set of more than two substantially horizontally oriented comminution drum assemblies sequentially engage lower portions of the whole tree or brush type vegetation that exist immediately below the portions that are comminuted by each successive comminution drum assembly.

Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.

Abstract: A powered fastener driver includes a cylinder and a drive piston within the cylinder being acted on by a driving force resulting from a pressure differential. The powered fastener further includes a drive blade coupled to the drive piston and operable to drive a fastener, and an adjustable valve for selectively introducing air from ambient atmosphere into the cylinder, thereby changing the pressure differential acting on the drive piston. By adopting a self-contained vacuum generating means as described above, the present invention does not rely on any external vacuum source and powered fastener driver can be used and carried with conveniently.